Skip to main content

Rubius Therapeutics, Inc. (RUBY)

NASDAQ: RUBY · IEX Real-Time Price · USD
13.43 0.32 (2.44%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap1.21B
Revenue (ttm)n/a
Net Income (ttm)-182.07M
Shares Out89.87M
EPS (ttm)-1.99
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume188,953
Open13.21
Previous Close13.11
Day's Range12.87 - 13.49
52-Week Range6.21 - 38.71
Beta2.57
AnalystsBuy
Price Target30.40 (+126.4%)
Earnings DateNov 8, 2021

About RUBY

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

IndustryBiotechnology
IPO DateJul 18, 2018
CEOPablo Cagnoni
Employees268
Stock ExchangeNASDAQ
Ticker SymbolRUBY
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for RUBY stock is "Buy." The 12-month stock price forecast is 30.40, which is an increase of 126.36% from the latest price.

Price Target
$30.40
(126.36% upside)
Analyst Consensus: Buy

News

Rubius Therapeutics Named to the List of Top Places to Work in Massachusetts by the Boston Globe and Top 3 Best Place...

Company Earns Spot on Both Lists for Second Year in a Row Company Earns Spot on Both Lists for Second Year in a Row

6 days ago - GlobeNewsWire

Rubius Therapeutics to Host Virtual Preclinical Pipeline and Platform Technology Day on December 16, 2021

CAMBRIDGE, Mass., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

1 week ago - GlobeNewsWire

Rubius Therapeutics to Participate in Evercore ISI 4th Annual HealthCONx Conference

CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

2 weeks ago - GlobeNewsWire

Rubius Therapeutics Presents Preclinical Data for RTX-224, a Broad Immune Costimulatory Agonist, at the Society for I...

U.S. FDA Recently Cleared Investigational New Drug Application for RTX-224 U.S. FDA Recently Cleared Investigational New Drug Application for RTX-224

3 weeks ago - GlobeNewsWire

Rubius Therapeutics to Participate in Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

4 weeks ago - GlobeNewsWire

Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for RTX-224, Rubius' Third Oncology Candidate Clinical Results Expected by Year-End or First Quarter 2022 in Phase 1 T...

1 month ago - GlobeNewsWire

Is a Surprise Coming for Rubius Therapeutics (RUBY) This Earnings Season?

Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

Rubius Therapeutics to Announce Third Quarter 2021 Financial Results

CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

1 month ago - GlobeNewsWire

Rubius Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference and H.C. Wainwright...

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent...

3 months ago - GlobeNewsWire

Rubius Therapeutics Appoints Jim Jogerst as Chief Business Officer

CAMBRIDGE Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entir...

3 months ago - GlobeNewsWire

Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoing Phase 1/2 Clinical Trial for the Treatment of Patients with Advanced Solid Tumors

3 months ago - GlobeNewsWire

Should You Buy Rubius Therapeutics (RUBY) Ahead of Earnings?

Rubius Therapeutics (RUBY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

5 Drug/Biotech Stocks Set to Outpace Q2 Earnings Estimates

Let us take a look at some drug/biotech stocks - FSTX, HALO, KNTE, RUBY and SPRB - that are poised to beat on second-quarter earnings.

Other symbols:FSTXHALOKNTESPRB
4 months ago - Zacks Investment Research

Rubius Therapeutics to Announce Second Quarter 2021 Financial Results

CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

4 months ago - GlobeNewsWire

Rubius Therapeutics Announces Publication of RTX-240 Preclinical Data in Cancer Immunology, Immunotherapy

Preclinical Data Show RTX-240 Promotes T Cell and NK Cell Activity Demonstrating Efficacy and Improved Safety Compared with a 4-1BB Agonist Antibody Preclinical Data Show RTX-240 Promotes T Cell and NK ...

4 months ago - GlobeNewsWire

Rubius Therapeutics Announces First Patient Dosed with RTX-240 in Combination with KEYTRUDA® (pembrolizumab) in Ongoi...

CAMBRIDGE, Mass., June 23, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entir...

5 months ago - GlobeNewsWire

Rubius Therapeutics to Participate in Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 20, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entir...

6 months ago - GlobeNewsWire

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive...

CAMBRIDGE, Mass., May 19, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entire...

6 months ago - GlobeNewsWire

4 Biotech Stocks That Have Already Doubled This Year So Far

Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.

Other symbols:BNTXENTXOCGN
6 months ago - Zacks Investment Research

Rubius Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

Positive Initial Data from Phase 1/2 Trial of RTX-240 in Advanced Solid Tumors Demonstrated Single-Agent Activity Providing Initial Validation of the RED PLATFORM®;Dose Optimization and Enrollment Conti...

6 months ago - GlobeNewsWire

Rubius Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of RTX-321 for the Treatment of HPV 16-Po...

CAMBRIDGE, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

7 months ago - GlobeNewsWire

Rubius Therapeutics Presents Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advance...

CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an enti...

7 months ago - GlobeNewsWire

FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings

Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...

8 months ago - Benzinga

3 Biotech Stocks to Avoid Right Now

Here's why these attention-grabbing stocks could be toxic to your portfolio.

Other symbols:OCGNSAVA
8 months ago - The Motley Fool

Implied Volatility Surging for Rubius Therapeutics (RUBY) Stock Options

Investors need to pay close attention to Rubius Therapeutics (RUBY) stock based on the movements in the options market lately.

8 months ago - Zacks Investment Research